Skip to main content
SpringerLink
Log in

GlaxoSmithKline (GSK) has issued a Health Canada-endorsed public communication addressing public concerns about safety of Avandia

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Health Canada.Cardiac Safety of PrAVANDIA (Rm) (rosiglitazone maleate). Media Release: 30 May 2007. Available from: URL: http://www.hc-sc.gc.ca

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

GlaxoSmithKline (GSK) has issued a Health Canada-endorsed public communication addressing public concerns about safety of Avandia. React. Wkly. 1155, 5 (2007). https://doi.org/10.2165/00128415-200711550-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711550-00013

Keywords

Search

Navigation